{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:24Z","timestamp":1791919464102,"version":"4.3.4"},"reference-count":173,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273954"],"award-info":[{"award-number":["82273954"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["ZDB2020021"],"award-info":[{"award-number":["ZDB2020021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research Project of Jiangsu Provincial Health Commission","award":["82273954"],"award-info":[{"award-number":["82273954"]}]},{"name":"Key Research Project of Jiangsu Provincial Health Commission","award":["ZDB2020021"],"award-info":[{"award-number":["ZDB2020021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Targeting the intrinsic apoptotic pathway regulated by B-cell lymphoma-2 (BCL-2) antiapoptotic proteins can overcome the evasion of apoptosis in cancer cells. BCL-2 inhibitors have evolved into an important means of treating cancers by inducing tumor cell apoptosis. As the most extensively investigated BCL-2 inhibitor, venetoclax is highly selective for BCL-2 and can effectively inhibit tumor survival. Its emergence and development have significantly influenced the therapeutic landscape of hematological malignancies, especially in chronic lymphocytic leukemia and acute myeloid leukemia, in which it has been clearly incorporated into the recommended treatment regimens. In addition, the considerable efficacy of venetoclax in combination with other agents has been demonstrated in relapsed and refractory multiple myeloma and certain lymphomas. Although venetoclax plays a prominent antitumor role in preclinical experiments and clinical trials, large individual differences in treatment outcomes have been characterized in real-world patient populations, and reduced drug sensitivity will lead to disease recurrence or progression. The therapeutic efficacy may vary widely in patients with different molecular characteristics, and key genetic mutations potentially result in differential sensitivities to venetoclax. The identification and validation of more novel biomarkers are required to accurately predict the effectiveness of BCL-2 inhibition therapy. Furthermore, we summarize the recent research progress relating to the use of BCL-2 inhibitors in solid tumor treatment and demonstrate that a wealth of preclinical models have shown promising results through combination therapies. The applications of venetoclax in solid tumors warrant further clinical investigation to define its prospects.<\/jats:p>","DOI":"10.3390\/cancers15204957","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:46:13Z","timestamp":1697114773000},"page":"4957","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers"],"prefix":"10.3390","volume":"15","author":[{"given":"Jiaxuan","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C. S.","family":"Huang","sequence":"additional","affiliation":[{"name":"Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia"},{"name":"Department of Medical Biology, University of Melbourne, Melbourne, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8533-1938","authenticated-orcid":false,"given":"Quan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-2531","authenticated-orcid":false,"given":"Bing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Brown","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Schlis","year":"2008","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/hep.23836","article-title":"The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib","volume":"52","author":"Hikita","year":"2010","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nor Hisam, N.S., Ugusman, A., Rajab, N.F., Ahmad, M.F., Fenech, M., Liew, S.L., and Mohamad Anuar, N.N. (2021). Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091353"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: A non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","article-title":"A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer","volume":"9","author":"Lok","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20075","DOI":"10.18632\/oncotarget.24744","article-title":"S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth","volume":"9","author":"Casara","year":"2018","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","article-title":"Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/annonc\/mdh317","article-title":"A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors","volume":"15","author":"Marshall","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","article-title":"5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen","volume":"27","author":"Moore","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/bloodadvances.2021004233","article-title":"Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)","volume":"5","author":"Walker","year":"2021","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","article-title":"AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x(L), Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia","volume":"26","author":"Balachander","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41420-021-00505-0","article-title":"A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma","volume":"7","author":"Arulananda","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Patterson, C.M., Balachander, S.B., Grant, I., Pop-Damkov, P., Kelly, B., McCoull, W., Parker, J., Giannis, M., Hill, K.J., and Gibbons, F.D. (2021). Design and optimisation of dendrimer-conjugated Bcl-2\/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun. Biol., 4.","DOI":"10.1038\/s42003-020-01631-8"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3892\/ijo.2017.4028","article-title":"APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2\/Bcl-xl in HL-60 cells","volume":"51","author":"Wang","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41419-021-04042-7","article-title":"Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2\/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2\/STAT3\/MCL-1 signaling pathway","volume":"12","author":"Luo","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mc.23458","article-title":"Therapeutic potential of the novel Bcl-2\/Bcl-X(L) dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer","volume":"61","author":"Qian","year":"2022","journal-title":"Mol. Carcinog."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100798","DOI":"10.1016\/j.neo.2022.100798","article-title":"Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2\/Bcl-X(L) dual inhibitor that induces Bax-dependent apoptosis","volume":"29","author":"Yao","year":"2022","journal-title":"Neoplasia"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bai, L., Chen, J., McEachern, D., Liu, L., Zhou, H., Aguilar, A., and Wang, S. (2014). BM-1197: A novel and specific Bcl-2\/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099404"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.oraloncology.2015.06.004","article-title":"BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma","volume":"51","author":"Acasigua","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sun, Y.L., Jiang, W.Q., Luo, Q.Y., Yang, D.J., Cai, Y.C., Huang, H.Q., and Sun, J. (2019). A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway. BMC Cancer, 20.","DOI":"10.1186\/s12885-019-6169-0"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.1038\/cddis.2014.365","article-title":"Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer","volume":"5","author":"Loriot","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nemati, F., de Montrion, C., Lang, G., Kraus-Berthier, L., Carita, G., Sastre-Garau, X., Berniard, A., Vallerand, D., Geneste, O., and de Plater, L. (2014). Targeting Bcl-2\/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0080836"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1182\/blood-2006-10-047951","article-title":"Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma","volume":"109","author":"Trudel","year":"2007","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-10-0822","article-title":"Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma","volume":"16","author":"Hwang","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1182\/blood-2011-09-378141","article-title":"Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process","volume":"119","author":"Rahmani","year":"2012","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2019.07.003","article-title":"Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway","volume":"461","author":"Yang","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Renner, O., Mayer, M., Leischner, C., Burkard, M., Berger, A., Lauer, U.M., Venturelli, S., and Bischoff, S.C. (2022). Systematic Review of Gossypol\/AT-101 in Cancer Clinical Trials. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020144"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: From pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: Changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: A phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed Duration of Venetoclax-Rituximab in Relapsed\/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study","volume":"37","author":"Kater","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood.2020009578","article-title":"Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy","volume":"138","author":"Ma","year":"2021","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Zhang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study","volume":"39","author":"Wierda","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2018-05-853564","article-title":"Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia","volume":"132","author":"Rogers","year":"2018","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(19)30253-4","article-title":"Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: Risk factors, prophylaxis, and treatment recommendations","volume":"7","author":"Tambaro","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: A single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined with Low-Dose Cytarabine for Previously Untreated Patients with Acute Myeloid Leukemia: Results From a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.clml.2021.07.029","article-title":"A Phase II Study of Venetoclax in Combination with Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma","volume":"21","author":"Gasparetto","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, with or without Bortezomib, in Patients with Relapsed or Refractory Multiple Myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: A phase 1\/2 trial","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: Results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood.2020006578","article-title":"A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref_73","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: A cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","article-title":"Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active","volume":"5","author":"Garcia","year":"2021","journal-title":"Blood Adv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdcr.2020.12.025","article-title":"B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma","volume":"8","author":"King","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients","volume":"130","author":"Cyrenne","year":"2017","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in understanding the mechanisms of resistance to BCL-2 inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-19-0029","article-title":"Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL","volume":"9","author":"Thangavadivel","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zhang, X., Qian, J., Wang, H., Wang, Y., Zhang, Y., Qian, P., Lou, Y., Jin, J., and Zhu, H. (2021). Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia. Biomark. Res., 9.","DOI":"10.1186\/s40364-021-00288-7"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.25796","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)\u2014Outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","article-title":"Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax","volume":"99","author":"Wang","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"106735","DOI":"10.1016\/j.leukres.2021.106735","article-title":"RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed\/refractory acute myeloid leukemia","volume":"111","author":"Chow","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wang, J., Ye, X., Fan, C., Zhou, J., Luo, S., Jin, J., Chen, D., Zheng, Y., Wu, C., and Zhu, X. (2020). Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML. Biomark. Res., 8.","DOI":"10.1186\/s40364-020-00246-9"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.2021013156","article-title":"Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2","volume":"139","author":"Mill","year":"2022","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s00432-022-03930-5","article-title":"Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia","volume":"148","author":"Fleischmann","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of ABT-199 sensitivity in human AML","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: Current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1002\/ajh.25719","article-title":"Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation","volume":"95","author":"Zhu","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of Venetoclax and Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia and IDH1\/2 Mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Buege, M.J., DiPippo, A.J., and DiNardo, C.D. (2018). Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations. Cancers, 10.","DOI":"10.3390\/cancers10060187"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-020-00186-y","article-title":"Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML","volume":"10","author":"Jasra","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41375-021-01468-y","article-title":"Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia","volume":"36","author":"Cathelin","year":"2022","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"E154","DOI":"10.1002\/ajh.26122","article-title":"Decitabine and venetoclax for IDH1\/2-mutated acute myeloid leukemia","volume":"96","author":"Venugopal","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/cncr.33675","article-title":"Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy","volume":"127","author":"Venugopal","year":"2021","journal-title":"Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/bjh.16166","article-title":"Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia","volume":"187","author":"Aldoss","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic Biomarkers of Sensitivity and Resistance to Venetoclax Monotherapy in Patients with Relapsed Acute Myeloid Leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naive Acute Myeloid Leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.25929","article-title":"Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia","volume":"95","author":"Aldoss","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-020-00973-4","article-title":"Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia","volume":"13","author":"Brinton","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_119","first-page":"1034","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Zhang","year":"2021","journal-title":"Haematologica"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/OTT.S336715","article-title":"Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine","volume":"15","author":"Zhang","year":"2022","journal-title":"OncoTargets Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3324\/haematol.2021.278369","article-title":"AXL\/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia","volume":"107","author":"Post","year":"2021","journal-title":"Haematologica"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1080\/10428194.2020.1779255","article-title":"Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation","volume":"61","author":"Pan","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ccr.2013.06.002","article-title":"Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer","volume":"24","author":"Vaillant","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/onc.2015.287","article-title":"Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer","volume":"35","author":"Merino","year":"2016","journal-title":"Oncogene"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"OT-27-01","DOI":"10.1158\/1538-7445.SABCS20-OT-27-01","article-title":"Abstract OT-27-01: PALVEN: A phase 1b study of palbociclib, letrozole and venetoclax in estrogen receptor, BCL2-positive metastatic breast cancer","volume":"81","author":"Muttiah","year":"2021","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1200\/JCO.2021.39.15_suppl.1004","article-title":"Results from VERONICA: A randomized, phase II study of second-\/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA\/MBC)","volume":"39","author":"Lindeman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1158\/1078-0432.CCR-19-1872","article-title":"Dual Targeting of CDK4\/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer","volume":"26","author":"Whittle","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.canlet.2019.05.004","article-title":"Combined Bcl-2\/Src inhibition synergize to deplete stem-like breast cancer cells","volume":"457","author":"Sun","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/s41419-021-04262-x","article-title":"Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells","volume":"12","author":"Schroeder","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41467-019-08541-2","article-title":"Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy","volume":"10","author":"Haikala","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"13357","DOI":"10.2147\/OTT.S281519","article-title":"BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells","volume":"13","author":"Alhoshani","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/bcr3214","article-title":"gamma-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells","volume":"14","author":"Seveno","year":"2012","journal-title":"Breast Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Aka, Y., Karakas, B., Acikbas, U., Basaga, H., Gul, O., and Kutuk, O. (2021). Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target. Int. J. Biochem. Cell Biol., 137.","DOI":"10.1016\/j.biocel.2021.106028"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/15384047.2018.1423927","article-title":"The irreversible ERBB1\/2\/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells","volume":"19","author":"Booth","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbrc.2020.02.133","article-title":"Low DEDD expression in breast cancer cells indicates higher sensitivity to the Bcl-2-specific inhibitor ABT-199","volume":"525","author":"Liu","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/0008-5472.CAN-20-1601","article-title":"Hormonal Regulation of Semaphorin 7a in ER+ Breast Cancer Drives Therapeutic Resistance","volume":"81","author":"Crump","year":"2021","journal-title":"Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1940-6207.CAPR-21-0031","article-title":"Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer","volume":"15","author":"Young","year":"2022","journal-title":"Cancer Prev. Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/cdd.2015.73","article-title":"Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer","volume":"22","author":"Goodwin","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41419-017-0039-y","article-title":"Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells","volume":"9","author":"Lucantoni","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1078-0432.CCR-17-1606","article-title":"Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression","volume":"24","author":"Lochmann","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/1535-7163.MCT-16-0459","article-title":"Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors","volume":"16","author":"Lam","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/ncomms16078","article-title":"Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy","volume":"8","author":"Jeng","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41419-021-03855-w","article-title":"Predicting ROR1\/BCL2 combination targeted therapy of small cell carcinoma of the lung","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1038\/s41467-020-18372-1","article-title":"MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically","volume":"11","author":"Munkhbaatar","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/1878-0261.12454","article-title":"The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1\/S6 signaling","volume":"13","author":"Zhang","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/15384047.2020.1856756","article-title":"Epigenetic modulation of FBW7\/Mcl-1 pathway for lung cancer therapy","volume":"22","author":"Kim","year":"2021","journal-title":"Cancer Biol. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1007\/s00204-021-03147-4","article-title":"Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo","volume":"95","author":"Liu","year":"2021","journal-title":"Arch. Toxicol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41419-021-04029-4","article-title":"Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer","volume":"12","author":"Potter","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.7150\/thno.60349","article-title":"Discovery of Small Molecule Bak Activator for Lung Cancer Therapy","volume":"11","author":"Park","year":"2021","journal-title":"Theranostics"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Tan, Y., Li, X., Tian, Z., Chen, S., Zou, J., Lian, G., Chen, S., Huang, K., and Chen, Y. (2021). TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Biochem. Pharmacol., 189.","DOI":"10.1016\/j.bcp.2020.114085"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1007\/s10620-018-5253-7","article-title":"BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo","volume":"63","author":"Zhou","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1111\/bph.14505","article-title":"ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca(2+)-signalling dysregulation or toxicity in pancreatic acinar cells","volume":"176","author":"Jakubowska","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"King, H.M., Rana, S., Kubica, S.P., Mallareddy, J.R., Kizhake, S., Ezell, E.L., Zahid, M., Naldrett, M.J., Alvarez, S., and Law, H.C. (2021). Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. Bioorg. Med. Chem. Lett., 43.","DOI":"10.1016\/j.bmcl.2021.128061"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11010-020-03796-6","article-title":"Bcl-2\/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2","volume":"472","author":"Morimoto","year":"2020","journal-title":"Mol. Cell. Biochem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/mol.119.116855","article-title":"CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax","volume":"96","author":"Kour","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Lafontaine, J., Cardin, G.B., Malaquin, N., Boisvert, J.S., Rodier, F., and Wong, P. (2021). Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells. Cancers, 13.","DOI":"10.3390\/cancers13030386"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41419-020-02910-2","article-title":"The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA","volume":"11","author":"Muenchow","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1038\/s41388-018-0212-5","article-title":"BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis","volume":"37","author":"Heinicke","year":"2018","journal-title":"Oncogene"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Fairchild, C.K., Floros, K.V., Jacob, S., Coon, C.M., Puchalapalli, M., Hu, B., Harada, H., Dozmorov, M.G., Koblinski, J.E., and Smith, S.C. (2021). Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA. Cancers, 13.","DOI":"10.3390\/cancers13102310"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1158\/1078-0432.CCR-18-0277","article-title":"The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity","volume":"25","author":"Heisey","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1158\/1535-7163.MCT-15-0846","article-title":"Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro","volume":"15","author":"Hoda","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.bbrc.2018.07.027","article-title":"ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma","volume":"503","author":"Wang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"6772","DOI":"10.1038\/s41388-021-02117-5","article-title":"Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer","volume":"40","author":"Yin","year":"2021","journal-title":"Oncogene"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Perimenis, P., Galaris, A., Voulgari, A., Prassa, M., and Pintzas, A. (2016). IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2606-5"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"O\u2019Farrell, A.C., Jarzabek, M.A., Lindner, A.U., Carberry, S., Conroy, E., Miller, I.S., Connor, K., Shiels, L., Zanella, E.R., and Lucantoni, F. (2020). Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models. Cancers, 12.","DOI":"10.3390\/cancers12102978"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2020.10.001","article-title":"A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3beta signaling","volume":"498","author":"Yu","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"10727","DOI":"10.1007\/s00432-023-04926-5","article-title":"Osimertinib is a dual inhibitor of hepatocellular carcinoma and angiogenesis in an EGFR-independent manner, and synergizes with venetoclax","volume":"149","author":"Huang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Yu, X., Dobrikov, M., Keir, S.T., Gromeier, M., Pastan, I.H., Reisfeld, R., Bigner, D.D., and Chandramohan, V. (2019). Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210608"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/jcmm.17636","article-title":"Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells","volume":"27","author":"Adamova","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3892\/mmr.2015.4715","article-title":"Curcumin enhances the antitumor effect of ABT-737 via activation of the ROS-ASK1-JNK pathway in hepatocellular carcinoma cells","volume":"13","author":"Zheng","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.3748\/wjg.v22.i15.3962","article-title":"Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms","volume":"22","author":"Ren","year":"2016","journal-title":"World J. Gastroenterol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/20\/4957\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:05:31Z","timestamp":1760130331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/20\/4957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":173,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15204957"],"URL":"https:\/\/doi.org\/10.3390\/cancers15204957","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]}}}